BioSight
Companies
SIGA TECHNOLOGIES INC logo

SIGA

NASDAQNEW YORK, NY
SIGA TECHNOLOGIES INC

SIGA Technologies develops and commercializes antiviral drugs, primarily TPOXX, for treating infectious diseases including smallpox and mpox. SIGA generates revenue from government contracts with the U.S. Biomedical Advanced Research and Development Authority (BARDA) and international biodefense customers, while also pursuing development of alternative formulations and uses of its existing products. SIGA's pipeline includes potential new products in preclinical and clinical development stages.

Price history not yet available for SIGA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar